导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.08% | 1687/4773 |
| 近一周 | -1.49% | 2219/5465 |
| 近一月 | 2.85% | 179/5421 |
| 近一季 | 5.33% | 319/5231 |
| 近半年 | -1.18% | 1710/4920 |
| 近一年 | 5.20% | 1745/4394 |
| 近两年 | 31.00% | 2242/2954 |
| 近三年 | 29.22% | 1114/2253 |
| 成立以来 | 66.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.38% 952/4961 |
-11.60% 4312/5312 |
- - |
- - |
| 2025 | 5.50% 2995/4813 |
-3.05% 3020/3635 |
5.87% 532/4076 |
-1.63% 3962/4524 |
4.48% 525/4813 |
| 2024 | 27.46% 189/3463 |
9.76% 115/2808 |
3.23% 276/3014 |
12.63% 2309/3129 |
-0.12% 1325/3463 |
| 2023 | 1.89% 341/2656 |
3.14% 1253/2280 |
1.97% 186/2385 |
3.63% 178/2515 |
-6.52% 1809/2655 |
| 2022 | -3.30% 64/2207 |
2.08% 81/1919 |
0.78% 1526/2016 |
-5.85% 87/2113 |
-0.16% 1569/2208 |
| 2021 | 2.99% 623/1822 |
6.63% 91/1255 |
-2.20% 1194/1330 |
0.21% 468/1466 |
-1.45% 1366/1822 |
| 2020 | 10.44% 836/1250 |
-12.26% 880/1028 |
3.68% 933/1067 |
13.62% 312/1164 |
6.84% 741/1184 |
| 2019 | - - |
- - |
- - |
- - |
8.36% 322/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 建信沪深300红利ETF VS. 长安沪深300非周期A(740101) |